1.Sales and profit
See section β- Constellium Se had $8.4B of revenue in fiscal 2025, up 15.2% on the year before.
- Constellium Se made $273M of net profit in fiscal 2025. From fiscal 2022 to 2025, diluted EPS grew β2.9% a year.
Constellium Se
CSTM NYSE Secondary Smelting & Refining Of Nonferrous Metals Financials FY2022βFY2025
Constellium Se had $8.4B of revenue in fiscal 2025, up 15.2% on the year before.
- Today
- 4.9%
- Previous close
- $23.41
- Market cap
- $3.4B
- P/E
- 8.0x
- Day range
-
$23.69 $24.58
- 52-week range
-
$14.75 $36.15
Last close Β· Oct 27, 2026
$24.56
+$7.71 (+45.76%) past year
KIRAβs summary AI analyst
Hi! I read Constellium Seβs latest annual report (fiscal 2025). Here is what stands out:
4 strengths
2.Cash and shareholders
See section β- Free cash flow was $159M in fiscal 2025, 1.9% of revenue.
- Constellium Se returned $115M to shareholders in fiscal 2025, 72% of free cash flow. The diluted share count fell 4.1%.
- In the last 12 months, insiders bought $0.2M and sold $12.2M of shares on the open market.
3.Financial health
See section β- Constellium Se owes $1.9B more than it holds in cash.
- Constellium Se passes 8 of 8 financial health tests (Piotroski F-score).
Constellium Se in 30 seconds
Good So-so Weak
Good
Are sales growing?
+15.2%
Yes. Sales grew 15.2% last year.
So-so
Does it make a profit?
3.2%
A little. It keeps 3.2% of every sale as profit.
So-so
Does profit turn into cash?
1.9%
Partly. 1.9% of sales ends up as free cash.
Good
How healthy are the accounts?
8 / 8
Solid. It passes 8 of 8 health tests.
For information
How is the share priced?
8.0x
One share costs 8.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$3.4B
Oct 27 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
8.0x
On $3.08 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA summarises the numbers
-
Constellium Se had $8.4B of revenue in fiscal 2025, up 15.2% on the year before.
Revenue
FY22
Revenue $8.5B
FY23
Revenue $7.8B
FY24
Revenue $7.3B
FY25
Revenue $8.4B
Revenue
Q1 '24
Revenue $1.9B
Q2 '24
Revenue $1.9B
Q3 '24
Revenue $1.8B
Q4 '24
Revenue $1.7B
Q1 '25
Revenue $2.0B
Q2 '25
Revenue $2.1B
Q3 '25
Revenue $2.2B
Q4 '25
Revenue $2.2B
Q1 '26
Revenue $2.5B
Margins, % of revenue
FY22
Gross β
Operating β
Net 3.6%
FCF 0.9%
FY23
Gross β
Operating β
Net 1.9%
FCF 0.8%
FY24
Gross β
Operating β
Net 0.8%
FCF β1.5%
FY25
Gross β
Operating β
Net 3.2%
FCF 1.9%
Gross
Operating
Net
FCF
Margins, % of revenue
Q1 '24
Gross β
Operating β
Net 1.1%
FCF β2.0%
Q2 '24
Gross β
Operating β
Net 3.9%
FCF 2.8%
Q3 '24
Gross β
Operating β
Net 0.4%
FCF β2.2%
Q4 '24
Gross β
Operating β
Net β2.8%
FCF β5.2%
Q1 '25
Gross β
Operating β
Net 1.9%
FCF β0.6%
Q2 '25
Gross β
Operating β
Net 1.7%
FCF 1.8%
Q3 '25
Gross β
Operating β
Net 4.1%
FCF 1.1%
Q4 '25
Gross β
Operating β
Net 5.1%
FCF 5.0%
Q1 '26
Gross β
Operating β
Net 8.1%
FCF 0.0%
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Constellium Se made $273M of net profit in fiscal 2025.
From fiscal 2022 to 2025, diluted EPS grew β2.9% a year.
Net income
FY22
Net income $308M
FY23
Net income $152M
FY24
Net income $56.0M
FY25
Net income $273M
Net income
Q1 '24
Net income $21.0M
Q2 '24
Net income $76.0M
Q3 '24
Net income $7.0M
Q4 '24
Net income β$48.0M
Q1 '25
Net income $37.0M
Q2 '25
Net income $36.0M
Q3 '25
Net income $88.0M
Q4 '25
Net income $112M
Q1 '26
Net income $199M
Diluted EPS
FY22
Diluted EPS $2.10
FY23
Diluted EPS $1.03
FY24
Diluted EPS $0.38
FY25
Diluted EPS $1.92
Diluted EPS
Q1 '24
Diluted EPS $0.14
Q2 '24
Diluted EPS $0.51
Q3 '24
Diluted EPS $0.05
Q4 '24
Diluted EPS β$0.32
Q1 '25
Diluted EPS $0.26
Q2 '25
Diluted EPS $0.25
Q3 '25
Diluted EPS $0.62
Q4 '25
Diluted EPS $0.79
Q1 '26
Diluted EPS $1.42
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was $159M in fiscal 2025, 1.9% of revenue.
Free cash flow
FY22
Free cash flow $76.0M
FY23
Free cash flow $66.0M
FY24
Free cash flow β$112M
FY25
Free cash flow $159M
Free cash flow
Q1 '24
Free cash flow β$37.0M
Q2 '24
Free cash flow $54.0M
Q3 '24
Free cash flow β$39.0M
Q4 '24
Free cash flow β$90.0M
Q1 '25
Free cash flow β$11.0M
Q2 '25
Free cash flow $37.0M
Q3 '25
Free cash flow $24.0M
Q4 '25
Free cash flow $109M
Q1 '26
Free cash flow $1.0M
Cash from operations vs capital spending
FY22
Cash from operations $365M
Capital spending $289M
FY23
Cash from operations $432M
Capital spending $366M
FY24
Cash from operations $301M
Capital spending $413M
FY25
Cash from operations $489M
Capital spending $330M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q1 '24
Cash from operations $37.0M
Capital spending $74.0M
Q2 '24
Cash from operations $138M
Capital spending $84.0M
Q3 '24
Cash from operations $65.0M
Capital spending $104M
Q4 '24
Cash from operations $61.0M
Capital spending $151M
Q1 '25
Cash from operations $58.0M
Capital spending $69.0M
Q2 '25
Cash from operations $114M
Capital spending $77.0M
Q3 '25
Cash from operations $99.0M
Capital spending $75.0M
Q4 '25
Cash from operations $218M
Capital spending $109M
Q1 '26
Cash from operations $73.0M
Capital spending $72.0M
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
KIRA summarises the numbers
-
Constellium Se returned $115M to shareholders in fiscal 2025, 72% of free cash flow.
The diluted share count fell 4.1%.
Dividends and buybacks
FY22
Dividends β
Buybacks $0.0M
FY23
Dividends β
Buybacks $0.0M
FY24
Dividends β
Buybacks $79.0M
FY25
Dividends β
Buybacks $115M
Dividends
Buybacks
Dividends and buybacks
Q1 '24
Dividends β
Buybacks $7.0M
Q2 '24
Dividends β
Buybacks $32.0M
Q3 '24
Dividends β
Buybacks $21.0M
Q4 '24
Dividends β
Buybacks $19.0M
Q1 '25
Dividends β
Buybacks $15.0M
Q2 '25
Dividends β
Buybacks $35.0M
Q3 '25
Dividends β
Buybacks $25.0M
Q4 '25
Dividends β
Buybacks $40.0M
Q1 '26
Dividends β
Buybacks $28.0M
Dividends
Buybacks
Diluted shares outstanding (annual)
FY22
Diluted shares 0.15B
FY23
Diluted shares 0.15B
FY24
Diluted shares 0.15B
FY25
Diluted shares 0.14B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $0.2M and sold $12.2M of shares on the open market.
Bought, 12 months
$0.2M
2 insiders
Sold, 12 months
$12.2M
13 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Jean-Christophe DeslarzesDirector | Bought | 1,490 | $27.24 | $0.0M | Form 4 |
| Jun 4, 2026 | John OrmerodDirector | Sold | 8,000 | $35.01 | $0.3M | Form 4 |
| May 28, 2026 | Marcus BeckerSVP Cpo | Sold | 10,391 | $34.93 | $0.4M | Form 4 |
| May 14, 2026 | Bradley Lee SoultzDirector | Bought | 2,500 | $33.84 | $0.1M | Form 4 |
| May 14, 2026 | Martin JarrettSVP Chief Innovation Officer | Sold | 4,716 | $33.46 | $0.2M | Form 4 |
| May 12, 2026 | Ludovic PiquierSVP Manuf Excellence & CTO | Sold | 1,000 | $33.57 | $0.0M | Form 4 |
| May 11, 2026 | Nicolas BrunSVP PA, Comm & Sust | Sold | 26,661 | $33.85 | $0.9M | Form 4 |
| May 8, 2026 | Stephane CorrePresident, AS&I | Sold | 5,000 | $33.52 | $0.2M | Form 4 |
| May 5, 2026 | Jack Q. GuoEVP & CFO | Sold | 25,201 | $32.62 | $0.8M | Form 4 |
| May 5, 2026 | Michiel BrandjesDirector | Sold | 10,400 | $31.25 | $0.3M | Form 4 |
| May 1, 2026 | Jean-Christophe DeslarzesDirector | Bought | 1,325 | $31.13 | $0.0M | Form 4 |
| May 1, 2026 | Philippe HoffmannPresident, A&T | Sold | 50,000 | $31.92 | $1.6M | Form 4 |
| May 1, 2026 | Stephane CorrePresident, AS&I | Sold | 5,000 | $32.04 | $0.2M | Form 4 |
| May 1, 2026 | Philip Ryan JurkovicSVP & CHRO | Sold | 48,784 | $32.01 | $1.6M | Form 4 |
| Mar 16, 2026 | Marcus BeckerSVP Cpo | Sold | 10,000 | $25.09 | $0.3M | Form 4 |
| Mar 10, 2026 | Stephane CorrePresident, AS&I | Sold | 1,500 | $25.89 | $0.0M | Form 4 |
| Mar 10, 2026 | Ingrid JoergCEO, Director | Sold | 4,614 | $25.87 | $0.1M | Form 4 |
| Mar 10, 2026 | Philippe HoffmannPresident, A&T | Sold | 4,728 | $25.87 | $0.1M | Form 4 |
| Mar 10, 2026 | Philip Ryan JurkovicSVP & CHRO | Sold | 29,900 | $25.87 | $0.8M | Form 4 |
| Mar 10, 2026 | Marcus BeckerSVP Cpo | Sold | 1,113 | $25.87 | $0.0M | Form 4 |
| Mar 10, 2026 | Jack Q. GuoEVP & CFO | Sold | 41,717 | $25.87 | $1.1M | Form 4 |
| Mar 9, 2026 | Nicolas BrunSVP PA, Comm & Sust | Sold | 17,701 | $24.67 | $0.4M | Form 4 |
| Mar 4, 2026 | Philippe HoffmannPresident, A&T | Sold | 80,000 | $26.45 | $2.1M | Form 4 |
| Mar 2, 2026 | Jean-Christophe DeslarzesDirector | Bought | 1,665 | $24.77 | $0.0M | Form 4 |
| Feb 27, 2026 | Stephane CorrePresident, AS&I | Sold | 3,000 | $24.69 | $0.1M | Form 4 |
| Feb 26, 2026 | Isabelle Boccon-GibodDirector | Sold | 10,000 | $25.77 | $0.3M | Form 4 |
| Feb 25, 2026 | Stephane CorrePresident, AS&I | Sold | 3,200 | $25.71 | $0.1M | Form 4 |
| Feb 23, 2026 | Stephen Charles WaltersSVP GC & Secretary | Sold | 1,500 | $25.39 | $0.0M | Form 4 |
| Feb 20, 2026 | Marcus BeckerSVP Cpo | Sold | 15,570 | $25.58 | $0.4M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Constellium Se can carry it.
KIRA summarises the numbers
-
Constellium Se owes $1.9B more than it holds in cash.
Cash vs debt (incl. leases)
FY22
Cash $176M
Debt β
FY23
Cash $223M
Debt $2.0B
FY24
Cash $141M
Debt $1.9B
FY25
Cash $120M
Debt $2.0B
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $176M | $223M | $141M | $120M |
| Debt incl. finance leases | β | $2.0B | $1.9B | $2.0B |
| Debt / equity | β | 2.7x | 2.7x | 2.0x |
| Current ratio | β | 1.3x | 1.3x | 1.3x |
| Quick ratio | β | 0.5x | 0.5x | 0.5x |
| Total assets | β | $4.9B | $4.7B | $5.4B |
| Total liabilities | β | $4.2B | $4.0B | $4.4B |
| Shareholders' equity | $603M | $718M | $706M | $952M |
| Net debt (β = net cash) | β | $1.7B | $1.8B | $1.9B |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY22
Return on capital β
Return on equity 51.1%
Return on assets β
FY23
Return on capital β
Return on equity 23.0%
Return on assets 3.1%
FY24
Return on capital β
Return on equity 7.9%
Return on assets 1.2%
FY25
Return on capital β
Return on equity 32.9%
Return on assets 5.4%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
-
Constellium Se passes 8 of 8 financial health tests (Piotroski F-score).
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 4 | 4 / 8 | 8 / 8 |
| Accruals ratio | β | β5.7% | β5.1% | β4.3% |
| Altman Z'' | β | β | β | β |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
4 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $8.5B | $7.8B | $7.3B | $8.4B |
| Research and development | $46.0M | $52.0M | $49.0M | $51.0M |
| Interest expense | $96.0M | $101M | $99.0M | $102M |
| Pretax income | $150M | $232M | $135M | $408M |
| Income tax | β$165M | $75.0M | $75.0M | $133M |
| Net income | $308M | $152M | $56.0M | $273M |
| Diluted EPS | $2.10 | $1.03 | $0.38 | $1.92 |
| Diluted shares | 0.15B | 0.15B | 0.15B | 0.14B |
| Cash flow | ||||
| Cash from operations | $365M | $432M | $301M | $489M |
| Capital expenditure | $289M | $366M | $413M | $330M |
| Free cash flow | $76.0M | $66.0M | β$112M | $159M |
| Depreciation and amortization | $290M | $300M | $304M | $330M |
| Stock-based compensation | $18.0M | $22.0M | $25.0M | $19.0M |
| Acquisitions | $0.0M | $0.0M | β$3.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $79.0M | $115M |
| Dividends and buybacks | $0.0M | $0.0M | $79.0M | $115M |
| Balance sheet | ||||
| Cash and short-term investments | $176M | $223M | $141M | $120M |
| Total debt | β | $1.9B | $1.9B | $1.9B |
| Finance lease liabilities | β | $34.0M | $30.0M | $32.0M |
| Current assets | β | $2.0B | $1.8B | $2.3B |
| Current liabilities | β | $1.6B | $1.4B | $1.8B |
| Inventory | β | $1.2B | $1.2B | $1.4B |
| Property and equipment, net | β | $2.4B | $2.4B | $2.6B |
| Goodwill | β | $41.0M | $46.0M | $47.0M |
| Intangible assets | β | $104M | $97.0M | $88.0M |
| Total assets | β | $4.9B | $4.7B | $5.4B |
| Total liabilities | β | $4.2B | $4.0B | $4.4B |
| Shareholders' equity | $603M | $718M | $706M | $952M |
| Margins | ||||
| Net margin | 3.6% | 1.9% | 0.8% | 3.2% |
| FCF margin | 0.9% | 0.8% | β1.5% | 1.9% |
| Returns | ||||
| Return on equity | 51.1% | 23.0% | 7.9% | 32.9% |
| Return on assets | β | 3.1% | 1.2% | 5.4% |
| Return on tangible equity | 51.1% | 26.5% | 9.9% | 33.4% |
| Growth | ||||
| Revenue growth | β | β8.3% | β6.3% | 15.2% |
| Net income growth | β | β50.6% | β63.2% | 387.5% |
| EPS growth | β | β51.0% | β63.1% | 405.3% |
| FCF growth | β | β13.2% | β269.7% | β |
| Share count change | β | 1.0% | β0.3% | β4.1% |
| Financial health | ||||
| Debt / equity | β | 2.7x | 2.7x | 2.0x |
| Current ratio | β | 1.3x | 1.3x | 1.3x |
| Quick ratio | β | 0.5x | 0.5x | 0.5x |
| Capital allocation | ||||
| Capex / revenue | 3.4% | 4.7% | 5.6% | 3.9% |
| Stock comp / revenue | 0.2% | 0.3% | 0.3% | 0.2% |
| Payouts / FCF | 0.0% | 0.0% | β | 72.3% |
| Quality scores | ||||
| Piotroski F-score | β | β | 4.0 | 8.0 |
| Accruals ratio | β | β5.7% | β5.1% | β4.3% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001563411). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.